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than standard therapy in controlling hematocrit levels and 
improving splenomegaly and PV-related symptoms. Only 
1 of 110 patients in the ruxolitinib arm compared with 6 
of 112 patients in the control arm experienced a thrombo-
embolic event through week 32. Grade ≥3 cytopenias were 
uncommon.
Keywords JAK inhibition · Myelofibrosis · 
Myeloproliferative neoplasm · Polycythemia vera · 
Ruxolitinib
Introduction
Philadelphia chromosome–negative myeloproliferative 
neoplasms (MPNs), including myelofibrosis (MF), poly-
cythemia vera (PV), and essential thrombocythemia (ET), 
are genetically related, but heterogeneous chronic diseases 
characterized by overactive signaling through the Janus 
kinase (JAK)-signal transducer and activator of transcrip-
tion (STAT) pathway as the central pathogenic mechanism 
[1–5]. The JAK–STAT pathway plays an essential role in 
normal hematopoiesis by mediating incoming signals from 
hematopoietic growth factors such as erythropoietin and 
thrombopoietin in hematopoietic stem cells [6]. The term 
“myelofibrosis” refers collectively to patients with de novo, 
primary myelofibrosis (PMF) and those with myelofibrotic 
transformation from PV to post-PV MF or from ET to post-
ET MF [7, 8].
Although our understanding of the relationship between 
MPN genotype and phenotype remains incomplete, tremen-
dous progress has been made in recent years in elucidating 
the complexity of somatic mutations that drive MPN patho-
genesis and influence patients’ prognoses. Prompted by the 
discovery of the JAK2V617F gain-of-function mutation in 
Abstract Myelofibrosis (MF) and polycythemia vera 
(PV) are BCR-ABL1-negative myeloproliferative neo-
plasms associated with somatic hematopoietic stem cell 
mutations leading to over activation of JAK–STAT signal-
ing. MF and PV are pathogenically related and share spe-
cific clinical features such as splenomegaly and constitu-
tional symptoms. The MF phenotype is dominated by the 
effects of progressive bone marrow fibrosis resulting in 
shortened survival. In contrast, elevated thrombosis risk 
due to erythrocytosis is the primary clinical concern in 
PV. Ruxolitinib, an oral JAK1/JAK2 inhibitor, is approved 
in the USA for the treatment of patients with intermedi-
ate- or high-risk MF and patients with PV who have had 
an inadequate response to or are intolerant of hydroxyurea. 
For MF, results of two phase III studies demonstrated that 
ruxolitinib therapy reduced spleen volume and MF-related 
symptom burden, improved quality-of-life measures, and 
was associated with prolonged overall survival. Treatment 
benefits were generally sustained with continued therapy. 
Dose-dependent cytopenias were common but generally 
manageable with transfusions (for anemia), dose reduction, 
or treatment interruption. Optimal dosing management is 
critical to maintain long-term treatment benefit, because 
cessation of therapy resulted in rapid return of symp-
toms to baseline levels. Results of the phase III PV trial 
showed that ruxolitinib was significantly more effective 
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more than 50 % of patients with PMF or ET and at least 
95 % of patients with PV [4], the importance of JAK–STAT 
pathway dysregulation in the pathogenesis of MPNs is now 
well established [5]. In addition to the JAK2V617F muta-
tion, which promotes constitutive activation of JAK2, other 
somatic stem cell mutations have been identified in patients 
with MPNs that lead to over activation of JAK–STAT sign-
aling, including mutations in the thrombopoietin receptor 
gene (MPL) [4, 5, 9] and the calreticulin gene (CALR) [5, 
10, 11] (Fig. 1 [10, 12]). In the vast majority of patients, 
JAK2, MPL, and CALR mutations appear to be mutually 
exclusive and are considered principal drivers of neoplastic 
myeloproliferation [10, 11]. However, the diagnostic value 
of these mutations is limited, as none is specific for any one 
type of MPN and a small minority of patients with MPNs 
lack JAK2, MPL, and CALR mutations [13, 14]. Further-
more, patients with MPNs often carry multiple additional 
mutations that may affect clinical phenotype and/or prog-
nosis [5, 14, 15].
In addition to its essential role in hematopoiesis, the 
JAK–STAT pathway is central to cytokine activation and 
signaling in the immune system [6]. It is well documented 
that patients with MF have abnormally high levels of cir-
culating inflammatory cytokines, including tumor necrosis 
factor alpha (TNF-α) and interleukin (IL)-6 [16], which 
appear to be fueled by aberrant cytokine secretion of both 
malignant and nonmalignant cells in the bone marrow [17]. 
Moreover, JAK1 hyperactivity has been noted in patients 
with MF [18] and may be due to cytokine hyperstimula-
tion. It is believed that abnormally high levels of circulating 
inflammatory cytokines are a major cause for the burden of 
constitutional symptoms in patients with MPNs [16, 19].
Ruxolitinib, an orally bioavailable inhibitor of JAK1 
and JAK2, is currently the only pharmacotherapy with 
approved indications in MF, and it has been recently 
approved by the US Food and Drug Administration for the 
treatment of patients with PV with an inadequate response 
to or intolerant of hydroxyurea. Ruxolitinib oral tablets are 
available in strengths of 5, 10, 15, 20, and 25 mg, allowing 
for individualized dosing regimens (per dosing recommen-
dations in the prescribing information [20]). In this review, 
we summarize the efficacy and safety data for ruxolitinib in 
both indications and discuss specific pharmacologic prop-
erties relevant for its safe and effective administration.
Ruxolitinib: general pharmacology
Ruxolitinib is an equipotent inhibitor of JAK1 [mean half 
maximal inhibitory concentration (IC50) = 3.3 nM] and 
JAK2 (mean IC50 = 2.8 nM) in vitro, with at least 100-
fold less inhibitory activity against JAK3 [18]. Early results 
obtained with a mouse model of JAK2V617F-induced 
MPN showed that ruxolitinib was highly effective in reduc-
ing splenomegaly and lowering IL-6 and TNF-α levels and 




















































Fig. 1  a Mutations underlying the pathobiology of myelofibrosis. 
Mutations commonly affect the JAK–STAT pathway, including those 
that occur directly in JAK2 such as the JAK2V617F mutation, or 
indirectly such as those in MPL, which encodes the thrombopoietin 
receptor, or in CALR, which may activate STATs through an unknown 
mechanism. Somatic mutations in epigenetic modifiers can also result 
in increased myeloproliferation, survival, and cytokine expression in 
myelofibrosis. From [12]. Copyright © 2014. b The approximate pro-
portion of patients with JAK2, MPL, and CALR mutations was exam-
ined in 203 patients with primary myelofibrosis. From [10].Copyright 
© 2013 Massachusetts Medical Society. Reprinted with permission 
from Massachusetts Medical Society. CALR calreticulin, JAK Janus 
kinase, MPL myeloproliferative leukemia virus oncogene, STAT sig-
nal transducer and activator of transcription
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cytokine levels were subsequently confirmed in phase II 
and III clinical studies and are believed to be integral to the 
efficacy of ruxolitinib [16, 21].
Ruxolitinib has a terminal half-life of approximately 
3 h [22] and is predominantly metabolized by CYP3A4 
and to a lesser extent by CYP2C9, with 74 and 22 % of a 
ruxolitinib dose recovered in urine and feces, respectively, 
within 24 h of oral administration in healthy human vol-
unteers (<1 % was unchanged drug) [20, 23]. Ruxolitinib 
plasma exposure [area under the curve from time 0 extrapo-
lated to infinite time (AUC0–inf)] increased by 91 and 27 % 
following concomitant administration of ketoconazole (a 
potent CYP3A4 inhibitor) and erythromycin (a moderate 
CYP3A4 inhibitor), respectively [24]. Pretreatment with 
the potent CYP3A4 inducer rifampin resulted in a 71 % 
decrease in ruxolitinib AUC0–inf, but had a limited impact 
on the overall pharmacodynamic activity, which decreased 
by 10 % [24]. This may be explained in part by an increase 
in the relative abundance of active ruxolitinib metabolites 
with rifampin coadministration [24].
Myelofibrosis
Natural history and prognosis
MF is a chronic disease marked by progressive bone mar-
row fibrosis, ineffective erythropoiesis, excess production 
of dysplastic megakaryocytes, extramedullary hematopoie-
sis, systemic inflammation with excess circulating levels 
of proinflammatory cytokines, cachexia, and shortened 
survival [16, 25–27]. The development and progression of 
fibrosis in the marrow is likely a reaction by stromal cells 
to the malignant hematopoietic stem cell clones and even-
tually leads to cytopenias (ineffective hematopoiesis) and/
or to extramedullary hematopoiesis as compensation for the 
diminished capacity of the bone marrow [28, 29]. The main 
clinical manifestations of MF include splenomegaly and a 
variety of troublesome symptoms (Fig. 2) [25, 26, 30, 31], 
which are a major source of morbidity and poor quality of 
life (QoL) [32–35]. Common symptoms include abdominal 
discomfort, early satiety, itching, bone pain, muscle pain, 
fatigue, dyspnea, and insomnia [31, 35]. Many patients 
also experience anemia, which may necessitate red blood 
cell transfusions [25, 32–34], and hepatomegaly is com-
mon among patients who underwent palliative splenectomy 
[36–38]. Patients with MF have an increased risk of devel-
oping secondary acute myeloid leukemia [39]. Leukemic 
transformation is thought to result from the accumulation 
of deleterious genetic events in addition to the mutations 
affecting JAK–STAT signaling, but the precise contribution 
of individually acquired mutations to the process of trans-
formation is not well understood [40].
Among patients with MPNs, those with PMF have the 
worst prognosis, with a median life expectancy of 6 years at 
the time of diagnosis [14]. Patients with MF may die from a 
variety of complications related to disease progression [32, 
41]. Risk factors for shortened survival that have been vali-
dated in various prognostic models include age >65 years, 
constitutional symptoms (fever, night sweats, weight loss), 
hemoglobin <10 g/dL, leukocytes >25 × 109/L, circulat-
ing blasts ≥1 % [32, 34], unfavorable karyotype, platelets 
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Fig. 2  a Prevalence of disease characteristics at diagnosis of 525 
patients with primary myelofibrosis examined by the International 
Working Group for Myeloproliferative Neoplasms Research and 
Treatment [34]. b Prevalence of common symptoms per the Mye-
loproliferative Neoplasm Symptom Assessment Form among 96 
patients with myelofibrosis and 145 patients with polycythemia vera 
[31]. BFI Brief Fatigue Inventory, Hb hemoglobin, MF myelofibro-
sis, PMF primary myelofibrosis, PV polycythemia vera, WBC white 
blood cell
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<100 × 109/L, and the need for red blood cell transfusions 
[33]. Median survival varies from approximately 11 years 
for those with low-risk disease to 2 years for those with 
high-risk disease [32]. Additional variables that have dem-
onstrated prognostic value outside of these models include 
mutations associated with worse (ASXL1) or better (CALR) 
prognosis [15, 42, 43], the number of mutations present 
[43], and the levels of circulating cytokines [44]. Current 
prognostic models also do not consider the potential impact 
of splenomegaly, fibrosis grade, low cholesterol, or comor-
bidities on survival [45–49].
Limitations of traditional therapies
Allogeneic hematopoietic stem cell transplantation is the 
only potentially curative option for MF and provides reso-
lution of bone marrow fibrosis in the majority of successful 
transplants [26, 50, 51]. However, because of the high risks 
of treatment-related morbidity and mortality, allogeneic 
hematopoietic stem cell transplantation is generally limited 
to younger patients with a survival expectancy of <5 years, 
with consideration of the patient’s overall benefit-risk pro-
file [26, 52]. Before the development of targeted inhibitors, 
conventional therapies addressing specific signs or symp-
toms of MF were used in a multimodal approach essen-
tially intended to provide palliation. Treatment with immu-
nomodulatory agents such as thalidomide, lenalidomide, 
or pomalidomide may benefit some patients with MF and 
anemia; however, recent studies suggest that these agents 
often have modest activity and/or provide limited long-
term benefit with no or marginal effects on splenomegaly 
[53–57]. Chemotherapies such as hydroxyurea, melpha-
lan, busulfan, and cladribine have been used mainly for the 
treatment of symptomatic splenomegaly; however, their 
efficacy was also modest and their use was associated with 
an increased burden of adverse events [58]. Importantly, 
conventional therapies have not demonstrated alleviation of 
constitutional symptoms such as fatigue [35] and have not 
been shown to result in improved overall survival or dis-
ease modification.
For patients with symptomatic splenomegaly who are 
intolerant of or refractory to pharmacotherapy, splenic irra-
diation and splenectomy are alternative palliative treatment 
options. However, both options have significant limitations. 
Palliative cytoreductive radiotherapy to the spleen, liver, 
or other sites of extramedullary hematopoiesis often pro-
vides nondurable responses and may cause or exacerbate 
cytopenias [59]. Splenectomy is associated with increased 
risk of complications and poor postoperative prognosis [37, 
60]. Therefore, splenectomy should be considered only 
for patients who have splenomegaly associated with portal 
hypertension, severe cytopenias, or other severe symptom, 
and who have no other treatment options.
Ruxolitinib for myelofibrosis
In November 2011, ruxolitinib was approved in the USA 
for the treatment of patients with intermediate- or high-risk 
MF [20]. Outside the USA, ruxolitinib is approved for the 
treatment of MF-related splenomegaly and symptoms in 
more than 80 countries. The initial approval of ruxolitinib 
was based on the results of two pivotal phase III clinical tri-
als, COntrolled MyeloFibrosis study with ORal JAK inhib-
itor Treatment (COMFORT)-I [21] and -II [61].
Efficacy
Patients with intermediate-2 or high-risk MF, platelet counts 
≥100 × 109/L, and splenomegaly received ruxolitinib or pla-
cebo in a randomized double-blind study (COMFORT-I), or 
ruxolitinib or best available therapy (BAT, most commonly 
hydroxyurea, 47 % of patients) in a randomized open-label 
study (COMFORT-II) [21, 61]. Based on assessments by 
magnetic resonance imaging or computed tomography, the 
primary endpoint, a ≥35 % reduction in total spleen volume 
(from baseline to week 24 for COMFORT-I and week 48 for 
COMFORT-II), was achieved by 41.9 % of patients in the 
ruxolitinib group versus 0.7 % in the placebo group in COM-
FORT-I and in 28 % in the ruxolitinib group versus 0 % in 
the BAT group in COMFORT-II [21, 61]. Overall, 97 % of 
patients in both studies experienced some degree of reduction 
in spleen volume upon treatment with ruxolitinib [21, 61]. 
Long-term ruxolitinib therapy was associated with marked 
and durable reductions in splenomegaly. In COMFORT-I, the 
median reduction from baseline in spleen volume was 34.9 % 
at week 96 and 34.1 % at week 144 in patients randomized to 
ruxolitinib [41, 62]. Patients in COMFORT-II who achieved 
a ≥35 % reduction in spleen volume had a 50 % probability 
of maintaining this level of improvement at week 144 [63]. 
At the time of the 3-year analyses, 49.7 and 45 % of patients 
randomized to ruxolitinib in COMFORT-I and COMFORT-
II, respectively, were still being treated [41, 62, 63].
An important secondary objective of the COMFORT trials 
was the assessment of changes in symptom burden, which is 
poorly addressed with traditional therapies. In COMFORT-I, 
45.9 % of patients who received ruxolitinib versus 5.3 % of 
those who received placebo (P < 0.001) achieved a ≥50 % 
improvement in total symptom score at week 24, as assessed by 
the modified Myelofibrosis Symptom Assessment Form ver-
sion 2 [21]. Marked improvements in role functioning and QoL 
per the European Organization for Research and Treatment of 
Cancer (EORTC) Quality-of-Life questionnaire core model 
(QLQ-C30) were also noted in ruxolitinib-treated patients 
(Fig. 3) [21, 64]. Similarly, in COMFORT-II, patients treated 
with ruxolitinib experienced mean improvements in fatigue, 
pain, dyspnea, insomnia, and appetite loss at week 48 per their 
responses on the EORTC-QLQ-C30, whereas patients treated 
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with BAT experienced mean worsening of those symptoms 
(Fig. 3) [61]. Some of the reduction in symptom burden may 
be due to a decrease in the proinflammatory state, because rux-
olitinib has been shown to decrease cytokine levels in patients 
with MF, which coincided with improvement in symptoms and 
splenomegaly [16, 65, 66]. Ruxolitinib-mediated symptom 
improvement and QoL benefits were durable among patients 
remaining on therapy based on recent 2- and 3-year follow-up 
data from the COMFORT studies [41, 62, 63].
In both COMFORT studies, efficacy was not depend-
ent on the presence of the JAK2V617F mutation [21, 61]. 
Moreover, the rapid reductions in splenomegaly and symp-
tom burden seen with ruxolitinib were not reflected by cor-
responding changes in allele burden, which generally were 
modest at the time of the primary analyses of COMFORT-I 
and COMFORT-II [21, 61, 63]. The absence of JAK2V617F 
should not preclude treatment with ruxolitinib and change 
in JAK2V617F allele burden is not useful as an indicator or 
predictor of short-time treatment success or as a surrogate 
measure of spleen size or symptom burden reduction.
Effect on biomarkers
A hallmark of advanced MF is the preponderance of 
cachexia and systemic inflammation, manifested by 
unwanted weight loss, hypocholesterolemia, low-grade 
fever, fatigue, and other constitutional symptoms [31, 
45, 67]. In addition, MF is characterized by increased 
plasma levels of proinflammatory cytokines such as IL-6, 
IL-8, TNF-α, and lipocalin-2 [16, 44, 68]. Some of these 
cytokines, such as lipocalin-2 and IL-8, have been impli-
cated directly in MF pathogenesis. Increased IL-8 expres-
sion in megakaryocytes derived from malignant stem cells 
may contribute to excess fibroblast proliferation in the bone 
marrow [69], whereas lipocalin-2 may promote oxidative 
damage of normal but not malignant CD34+ cells as well 
as osteoclastogenesis and fibrosis [68]. IL-6 is recognized 
as a mediator of cancer-related cachexia [70] and thus may 
be a driver of cachexia in MF.
Results from clinical studies of ruxolitinib in MF dem-
onstrated that ruxolitinib not only mitigated cachexia but 
also had a positive effect on various markers of inflamma-
tion. In the phase 1/2 study of ruxolitinib in MF, ruxolitinib 
promoted rapid reductions in plasma levels of a large num-
ber of inflammatory markers, including but not limited to 
IL-6, TNF-α, and C-reactive protein, an acute-phase marker 
of inflammation [16]. In COMFORT-I, ruxolitinib ver-
sus placebo was associated with significant improvements 
in weight (mean weight gain of 3.9 kg with ruxolitinib 
vs mean weight loss of 1.9 kg with placebo, P < 0.0001) 
and metabolic status (e.g., mean increase in total choles-
terol of 26.4 % vs mean decrease in 3.3 %, P < 0.0001) at 
24 weeks, and sustained improvement was observed with 
long-term therapy [71]. These metabolic improvements 
were accompanied by median reductions in plasma levels 
of close to 40 % for IL-6 and TNF-α and more than 70 % 
for C-reactive protein at week 24 [21]. In contrast, inflam-
mation markers showed no (TNF-α) or marginal improve-
ment (IL-6, C-reactive protein) with placebo. Furthermore, 
median plasma leptin levels increased approximately two-
fold with ruxolitinib and decreased slightly with placebo 
[21].
Results from animal models of MF suggest that 
increased production of proinflammatory cytokines origi-
nates not only from malignant cells but also from nonma-
lignant cells and is rapidly and potently inhibited by rux-
olitinib [17]. Of note, deletion of STAT3 in mutant clones 
has been shown to be insufficient to suppress inflamma-
tory signaling [17]. This finding supports the importance 
of inhibiting JAK–STAT signaling in nonmalignant cells to 
mitigate inflammation-related symptoms and would explain 
the effectiveness of ruxolitinib in providing rapid symptom 
































































































Fig. 3  a Mean change from baseline to week 24 in EORTC-QLQ-
C30 global health status and functional scales results in COMFORT-
I . From [21]. Copyright © 2012 Massachusetts Medical Society. 
Reprinted with permission from Massachusetts Medical Society. b 
Mean changes from baseline to week 48 in EORTC-QLQ-C30 symp-
tom scores in COMFORT-II. EORTC-QLQ-C30 European Organiza-
tion for Research and Treatment of Cancer Quality-of-Life question-
naire core model 30 . From [61]. Copyright © 2012 Massachusetts 
Medical Society. Reprinted with permission from Massachusetts 
Medical Society
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Survival and disease modification
Overall, data from the COMFORT studies suggest that rux-
olitinib was associated with improved overall survival com-
pared with placebo or BAT in patients with MF [21, 41, 61, 
72, 73]. Kaplan–Meier analyses of overall survival based on 
the intention-to-treat principle showed hazard ratios in favor 
of ruxolitinib versus placebo or BAT despite a potential bias 
in favor of the control arms caused by patient crossover to 
ruxolitinib [21, 61–63, 74]. In COMFORT-II, the survival 
advantage observed was independent of the mutation pro-
file, including prognostically detrimental mutations [75]. 
Furthermore, an ad hoc comparison of COMFORT-II data 
with those from a historical control group determined that 
patients with PMF receiving ruxolitinib had longer overall 
survival from the time of diagnosis than patients receiving 
conventional therapy [median survival 5 vs 3.5 years; hazard 
ratio (95 % CI) 0.61 (0.41–0.91), P = 0.0148], suggesting 
that ruxolitinib may modify the natural history of PMF [76]. 
This hypothesis is supported by long-term follow-up data 
from the phase II and III trials of ruxolitinib in MF show-
ing treatment-associated changes in bone marrow fibrosis 
and/or allele burden. Comparative analyses of bone mar-
row biopsies from patients enrolled in the ruxolitinib phase 
II study and a matched cohort treated with BAT showed 
that the proportions of patients who had improved or stabi-
lized bone marrow fibrosis after 1–5 years of treatment was 
greater with ruxolitinib than BAT [77]. Conversely, the odds 
of worsening fibrosis were lower with ruxolitinib versus 
BAT [odds ratio at 5 years (95 % CI) 0.07 (0.01–0.34)] [77]. 
A recent post hoc analysis from the COMFORT-I study fur-
ther showed that long-term therapy with ruxolitinib resulted 
in partial or complete molecular remission of JAK2V617F 
allele burden in 20 and six patients, respectively [78]. Of 
note, complete resolution of bone marrow fibrosis docu-
mented in two case reports of patients with post-PV MF 
appeared to be accompanied by complete molecular remis-
sion [79, 80]. Together, these findings suggest that long-
term therapy can result in profound disease modification, 
including sustained remission of bone marrow fibrosis and 
malignant clonal burden. Nevertheless, the general prolon-
gation of survival observed with ruxolitinib versus placebo 
or BAT in the COMFORT trials may be the result of overall 
improvement in patients’ health status, including the reduc-
tion of cachexia (unwanted weight loss) and other constitu-
tional symptoms, which are known prognostic factors in MF 
[32].
Safety and tolerability
The most common nonhematologic adverse reactions 
occurring in a greater proportion of patients receiving rux-
olitinib versus placebo were ecchymosis, dizziness, and 
headache (mostly grade 1 or 2), whereas abdominal pain 
and fatigue, which are typical disease-related symptoms, 
occurred less frequently in the ruxolitinib arm versus the 
placebo arm (Table 1) [21]. In COMFORT-II, the most 
common nonhematologic adverse events occurring in more 
patients treated with ruxolitinib versus BAT were diarrhea 
(23 vs 12 %) and asthenia (18 vs 10 %); most nonhemato-
logic adverse events were grade 1 or 2 [61].
Ruxolitinib inhibits normal erythropoietin and throm-
bopoietin signaling through JAK2 (through the erythropoi-
etin and thrombopoietin receptors, respectively) [6], often 
resulting in dose-dependent anemia and thrombocytopenia 
[21, 61]. Indeed, in the COMFORT studies, the most com-
mon hematologic adverse reactions with ruxolitinib were 
thrombocytopenia and anemia, some of which were grade 
3 or 4 (Table 2) [21, 61]. However, of 301 patients rand-
omized to ruxolitinib treatment in the two trials, only 1 
patient discontinued ruxolitinib for anemia and 2 patients 
discontinued ruxolitinib for thrombocytopenia. Instead, 
cytopenias were managed by dose modifications and treat-
ment interruptions or with red blood cell transfusions for 
anemia [21, 61]. In COMFORT-I, 77 % of patients with 
a baseline platelet count of 100–200 × 109/L and 39 % 
of patients with a baseline platelet count >200 × 109/L 
were receiving a lower dose at week 24 than at baseline 
[81]. Overall the incidence of adverse events decreased 
over time, with most occurring during the first 12 weeks 
Table 1  Nonhematologic adverse events in ≥10 % of patients who 
received ruxolitinib in COMFORT-I From [21]. Copyright © 2012 




Ruxolitinib (n = 155) Placebo (n = 151)
All grades Grade 3 or 4 All grades Grade 3 or 4
Fatigue 25.2 5.2 33.8 6.6
Diarrhea 23.2 1.9 21.2 0
Peripheral  
edema
18.7 0 22.5 1.3
Ecchymosis 18.7 0 9.3 0
Dyspnea 17.4 1.3 17.2 4.0
Dizziness 14.8 0.6 6.6 0
Nausea 14.8 0 19.2 0.7
Headache 14.8 0 5.3 0
Constipation 12.9 0 11.9 0
Vomiting 12.3 0.6 9.9 0.7
Pain in extrem-
ity
12.3 1.3 9.9 0
Insomnia 11.6 0 9.9 0
Arthralgia 11.0 1.9 8.6 0.7
Pyrexia 11.0 0.6 7.3 0.7
Abdominal pain 10.3 2.6 41.1 11.3
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of treatment [21, 41, 61, 63]. In both trials, mean hemo-
globin levels decreased initially, but recovered after the first 
8–12 weeks to new steady-state levels slightly lower than 
baseline [21, 61]. Similarly, ruxolitinib-treated patients 
initially required more blood transfusions than placebo-
treated patients, but transfusion rates gradually returned 
close to baseline values when assessed over a 36-week 
period [21]. In COMFORT-I, patients treated with rux-
olitinib who experienced grade 3 or 4 anemia had similar 
improvements in symptoms as those who did not have ane-
mia [21]. Mandatory dose reductions for thrombocytopenia 
occurred mostly during the first 8–12 weeks of treatment 
when mean platelet count decreased; after this period, a 
stabilization of mean platelet counts was observed [82].
In COMFORT-I, at the 3-year follow-up, four patients 
originally randomized to ruxolitinib and four patients ran-
domized to placebo experienced disease progression to 
secondary acute myeloid leukemia [21, 41, 62]. In COM-
FORT-II, at the 3-year follow-up, five patients (3.4 %) in 
the ruxolitinib arm and four patients (5.5 %) in the BAT 
arm experienced leukemic transformation [73].
Although rare adverse events of fever, respiratory dis-
tress, hypotension, and multi-organ failure have been 
reported after treatment discontinuation [20], experience 
from the placebo-controlled COMFORT-I study pro-
vided no evidence that treatment discontinuation per se 
was associated with serious adverse events [21, 41]. If a 
patient experiences one of these adverse events after the 
drug has been withdrawn or while tapering the dose, the 
intercurrent illness should be evaluate and treated, and 
restarting or increasing the dose of ruxolitinib should be 
considered [20]. If a patient needs to discontinue the use 
of ruxolitinib for a reason other than cytopenia, a gradual 
tapering of the dose by 5 mg twice daily each week may 
be considered to reduce the severity of returning symp-
toms [20]. Furthermore, the use of corticosteroids fol-
lowing discontinuation of ruxolitinib may be considered 
in specific cases where tapering of ruxolitinib is not pos-
sible (e.g., in cases of severe thrombocytopenia requiring 
immediate treatment discontinuation) and abrupt rux-
olitinib withdrawal results in an acute return of systemic 
inflammatory symptoms.
Dose management to maximize efficacy and minimize 
treatment‑related cytopenias
The recommended starting and maintenance dose of ruxoli-
tinib for the treatment of patients with MF is dependent on 
the baseline platelet count (Table 3) [20]. If response is insuf-
ficient, the dose may be increased beginning 4 weeks after 
initiation of therapy to a maximum of 25 mg twice daily for 
patients with starting platelet counts ≥100 × 109/L and to a 
maximum of 10 mg twice daily for patients with starting plate-
let counts of 50 to <100 × 109/L [82]. These increases may 
be undertaken in patients who fail to achieve a ≥50 % reduc-
tion in palpable spleen length or a ≥35 % reduction in spleen 
volume, as long as adequate platelet and absolute neutrophil 
counts are maintained [20]. Once-daily doses are not as effec-
tive as twice-daily dosing and should not be used unless spe-
cifically indicated [20]. If a dose is missed, the patient should 
take the next scheduled dose at the regular time [20]. Dose 
modifications should not be implemented on the basis of allele 
burden, because, as discussed above, allele burden reduction is 
not a clinically validated outcome marker in MF.
Experience from the COMFORT studies showed that 
careful monitoring of complete blood counts and adjustment 
of the dosing regimen accordingly are key to long-term ther-
apeutic success in patients with MF, as adherence to therapy 
and avoidance of extended interruptions are important fac-
tors in maintaining response to therapy [21, 61]. If ruxolitinib 
needs to be stopped, symptoms can be expected to return 
within 1 week, usually to pretreatment levels [20]. There-
fore, timely management of cytopenias with dose reductions, 
particularly during the first 3 months of therapy, is generally 
preferable to the risk of extended treatment interruptions that 
may reverse treatment gains. Prior to initiating ruxolitinib, a 
complete blood count must be performed, with subsequent 
monitoring during therapy every 2–4 weeks until doses sta-
bilize, and then as clinically indicated [20, 82]. For patients 
with a starting platelet count of ≥100 × 109/L, if at any point 
the platelet count falls below 50 × 109/L, treatment should 
be interrupted until the count recovers; for patients with 
a baseline platelet count of 50 to <100 × 109/L, treatment 
should be interrupted if platelet count falls below 25 × 109/L 
[20]. Frequent monitoring and prompt dose adjustments 
Table 2  Hematologic adverse eventsa in the phase III COMFORT trials, regardless of relation to study drug [21, 61]
BAT best available therapy, COMFORT COntrolled MyeloFibrosis study with ORal JAK inhibitor Treatment, NR not reported
a New or worsening hematologic events based on laboratory values
Percent of patients with any grade event  
(percent with grade 3 or 4 event)
COMFORT-I COMFORT-II
Ruxolitinib (n = 155) Placebo (n = 151) Ruxolitinib (n = 146) BAT (n = 73)
Anemia 96.1 (45.2) 86.8 (19.2) 96 (42) 94 (31)
Thrombocytopenia 69.7 (12.9) 30.5 (1.3) 68 (8) 29 (7)
Neutropenia 18.7 (7.1) 4.0 (2.0) NR NR
1132 Cancer Chemother Pharmacol (2016) 77:1125–1142
1 3
should be employed to avoid these occurrences. Detailed 
dosing recommendations for cytopenias can be found in the 
prescribing information [20, 82].
In patients requiring modifications from the starting 
dose, clinical evidence suggests that ruxolitinib can be 
effective long-term at titrated doses as low as 10 mg twice 
daily [82–84]. In trials of patients with MF with low plate-
let counts (between 50 and 100 × 109/L), dosing of ruxoli-
tinib was initiated at 5 mg twice daily followed by esca-
lation by 5 mg daily every 4 weeks to 10 mg twice daily 
or higher in patients with adequate platelet counts [83, 85]. 
Preliminary findings suggest that this dosing strategy is 
effective in reducing spleen volume and improving symp-
toms [83]. Although there are no contraindications for the 
use of ruxolitinib, treatment is not recommended in patients 
with baseline platelet counts <50 × 109/L [20].
Patients developing anemia may require blood transfu-
sions and/or dose modifications of ruxolitinib. Patients 
treated with ruxolitinib in COMFORT-II who also received 
erythropoietin-stimulating agents (ESA) had a decrease 
in the rate of grade 3 or 4 anemia within 6 weeks of the 
first administration of ESA, and administration of ESA did 
not appear to affect the efficacy of ruxolitinib in reducing 
spleen volume [86]. Severe neutropenia (absolute neutro-
phil count <0.5 × 109/L) is generally reversible with inter-
ruption of ruxolitinib therapy [81], which may be restarted 
once absolute neutrophil count recovers [20].
Polycythemia vera
Clinical manifestation and prognosis
By definition [87], patients with PV have no or only minor 
degrees of bone marrow fibrosis, and with a median life 
expectancy of 13.5 years from the time of diagnosis, their 
prognosis is much more favorable than that of patients 
with PMF [14]. However, patients with PV who have some 
degree of bone marrow fibrosis at diagnosis have a 22 % 
chance of developing post-PV MF within 10 years, com-
pared with a 7 % chance for patients with no bone marrow 
fibrosis at diagnosis [88]. Patients with PV typically have 
high levels of red blood cell mass, and keeping hemato-
crit levels below 45 % has been shown to be instrumental 
in minimizing the risk of cardiovascular death and major 
thrombosis [89]. However, although controlling hematocrit 
levels is the main concern in patients with PV, the disease is 
also associated with splenomegaly in approximately 40 % 
of patients [90], and with a considerable symptom burden, 
including high prevalence of fatigue (92 %) and pruritus 
(65 %) reported in a large survey (Fig. 2) [31].
First‑line therapy
Low-dose aspirin is the therapy of choice to reduce the 
overall risk of vascular events [91], and phlebotomy and/or 
cytoreductive therapy are commonly used to maintain hema-
tocrit levels of <45 % [89]. Hydroxyurea is the most common 
first-line cytoreductive therapy for patients at high risk of 
thrombosis who cannot undergo phlebotomy, require frequent 
phlebotomy, and/or have splenomegaly or PV-related symp-
toms [19]. However, some evidence suggests that hydrox-
yurea is possibly leukemogenic [92] and some patients may 
not tolerate hydroxyurea or may develop clinical resistance 
to hydroxyurea [93]. In addition to hydroxyurea, pegylated 
interferon is frequently used as first-line therapy for patients 
with PV, based on phase II clinical results that showed high 
rates of hematologic and molecular responses [94, 95].
Ruxolitinib for polycythemia vera
In December 2014, ruxolitinib was approved in the USA 
for the treatment of patients with PV who have had an 
Table 3  Ruxolitinib regular starting doses and starting doses for patients with concomitant use of strong CYP3A4 inhibitors or fluconazole [20]
Population Platelet count Ruxolitinib starting dose
Myelofibrosis
 Regular starting doses based on platelet count >200 × 109/L 20 mg twice daily
100 × 109 to 200 × 109/L 15 mg twice daily
50 × 109 to <100 × 109/L 5 mg twice daily
<50 × 109/L Not recommended
 Concomitant use of strong CYP3A4 inhibitors or  
fluconazole ≤200 mg
≥100 × 109 to 200 × 109/L 10 mg twice daily
50 × 109 to <100 × 109/L 5 mg twice daily
 Fluconazole >200 mg Any Concomitant use not recommended
Polycythemia vera
 Regular starting dose Any 10 mg twice daily
 Concomitant use of strong CYP3A4 inhibitors or fluconazole ≤200 mg Any 5 mg twice daily
 Fluconazole >200 mg Any Concomitant use not recommended
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inadequate response to or are intolerant of hydroxyurea 
[20]. Approval was based on the demonstration of clinical 
benefits in phase II and III clinical studies [96, 97].
Efficacy
In the open-label, multicenter phase III Randomized 
Study of Efficacy and Safety in Polycythemia Vera with 
JAK Inhibitor INCB018424 versus Best Supportive Care 
(RESPONSE), 222 patients with PV and resistance to or 
intolerance of hydroxyurea were randomized to receive 
ruxolitinib (starting dose: 10 mg twice daily) or stand-
ard therapy. Standard therapy consisted of hydroxyu-
rea (at tolerated doses) in 58.9 %, interferon in 11.6 %, 
pipobroman in 1.8 %, anagrelide in 7.1 %, immunomodu-
lators (e.g., lenalidomide, thalidomide) in 4.5 %, and no 
medication in 15.2 % of patients in this treatment arm 
[98]. Per inclusion criteria, patients had splenomegaly, 
exhibited phlebotomy dependence (defined as two or 
more phlebotomies during the 24 weeks before screen-
ing and one or more phlebotomies during the 16 weeks 
before screening), and did not receive prior treatment with 
a JAK inhibitor. The composite primary endpoint was the 
proportion of patients with both hematocrit control and 
a ≥35 % reduction in spleen volume from baseline to 
week 32. To achieve the endpoint of hematocrit control, 
a patient had to have ≤1 instance of phlebotomy eligibil-

















































































































































































































Fig. 4  Symptom assessment in the RESPONSE study [98]. a The 
percentage of patients with polycythemia vera who had ≥50 % 
reduction in the MPN-SAF total symptom score (with regard to 14 
symptoms; higher scores indicate greater severity of symptoms) and 
in total scores for the cytokine symptom cluster (tiredness, itching, 
muscle ache, night sweats, sweating while awake), the hypervis-
cosity symptom cluster (vision problems, dizziness, concentration 
problems, headache, numbness or tingling in the hands or feet, ring-
ing in the ears, skin redness), and the splenomegaly symptom clus-
ter (abdominal discomfort, early satiety) at week 32. b The median 
percentage change from baseline to week 32 in the score for each of 
the 14 symptoms on the MPN-SAF. Patients with data at both base-
line (value >0) and week 32 were included in the analyses for both 
panels. Negative values indicate a reduction in the severity of symp-
toms. MPN-SAF Myeloproliferative Neoplasm Symptom Assessment 
Form  From [98]. Copyright © 2015 Massachusetts Medical Society. 
Reprinted with permission from Massachusetts Medical Society
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instance of phlebotomy eligibility during the remainder of 
the 32-week study period.
The composite primary endpoint was achieved by 
20.9 % of patients in the ruxolitinib arm compared with 
0.9 % in the standard therapy arm (P < 0.001). Further 
analysis of the individual components of the primary end-
point showed that 60.0 % of patients in the ruxolitinib arm 
versus 19.6 % in the standard therapy arm had hematocrit 
control and 38.2 % in the ruxolitinib versus 0.9 % in the 
standard therapy arm (i.e., a single patient who received 
hydroxyurea) had a ≥35 % reduction in spleen volume 
from baseline to week 32. In addition, 49 % of patients 
receiving ruxolitinib compared with 5 % receiving standard 
therapy had a ≥50 % reduction in total symptom score, as 
assessed with a 14-item MPN Symptom Assessment Form 
patient diary. Median reductions in symptom score from 
baseline to week 32 for each of the 14 symptoms ranged 
from 37.1 % (numbness or tingling in hands or feet) to 
>90 % (itching, night sweats, sweating while awake, and 
early satiety). In contrast, standard therapy was associated 
with no or minimal symptom improvement or with symp-
tom worsening (Fig. 4). The difference in efficacy between 
the two arms was reflected in the mean changes from base-
line in EORTC-QLQ-C30 QoL and functioning scores, 
whereas ruxolitinib therapy resulted in overall improve-
ment, standard therapy was associated with worsening 
(Fig. 5) [98]. Recent longer-term follow-up data suggest 
that the benefits of ruxolitinib therapy are durable. Among 
patients who achieved the composite primary endpoint, 
only one patient had lost response at the 80-week follow-
up, and 82.7 % of patients were still receiving ruxolitinib 
after a median exposure of 111 weeks [99].
The superior benefit of ruxolitinib versus standard ther-
apy was also reflected in the discontinuation rates for the 
two treatment arms. After a median treatment exposure of 
81 weeks in the ruxolitinib arm, 15.5 % of patients had dis-
continued and none discontinued for protocol-defined lack 
of efficacy. In contrast, 96.4 % of patients randomized to 
standard therapy discontinued treatment or crossed over to 
ruxolitinib after a median treatment exposure of 34 weeks, 
and 87.5 % did so for lack of efficacy.
Safety and tolerability
The hematologic safety profile in the RESPONSE study 
was similar for both treatment arms (Table 4) [98]. The 
most common grade 3 and 4 hematologic events were 
lymphopenia (ruxolitinib: 15.5 % and 0.9 %, respec-
tively; standard therapy: 16.2 and 1.8 %, respectively). 
Two patients in the ruxolitinib arm (1.8 %) and no patients 
receiving standard therapy experienced grade 3 or 4 ane-
mia. Grade 3 or 4 thrombocytopenia occurred in six (5.4 %) 
patients receiving ruxolitinib and four (3.6 %) patients 
receiving standard therapy.
Nonhematologic adverse events were generally grade 
1 or 2 in both treatment arms [98]. Adverse events that 
were more common in the ruxolitinib versus the standard 
therapy arm (all-grade rates) included diarrhea (14.5 vs 
7.2 %), muscle spasms (11.8 vs 4.5 %), and dyspnea (10.0 
vs 1.8 %). In contrast, adverse events of pruritus, one of the 
most common symptoms of PV, occurred less frequently 
in the ruxolitinib versus the standard therapy arm (13.6 vs 
22.5 %), likely reflecting the superior efficacy of ruxoli-
tinib in symptom mitigation.
Within the 32-week study period, one patient treated 
with ruxolitinib versus six patients receiving standard ther-
apy experienced thromboembolic events. Two patients died 
after crossover from standard therapy to ruxolitinib. The 
causes of death were central nervous system hemorrhage 
and multi-organ failure-associated hypovolemic shock and 
a sudden unexplained decrease in hemoglobin [98].
Dosing
The recommended starting dose of ruxolitinib for the treat-
ment of patients with PV is 10 mg twice daily. Because 
of the different hematologic characteristics of PV and 
advanced MF, ruxolitinib-induced anemia and throm-
bocytopenia are much less common in patients with PV 
than they are in patients with intermediate- or high-risk 
MF. In the ruxolitinib arm of the RESPONSE study, only 
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Fig. 5  Mean change from baseline in EORTC-QLQ-C30 QoL and 
functioning scores at week 32 in patients with polycythemia vera in 
the RESPONSE study [98]. EORTC-QLQ-C30 European Organiza-
tion for Research and Treatment of Cancer Quality-of-Life ques-
tionnaire core model 30, QoL quality of life From [98]. Copyright 
© 2015 Massachusetts Medical Society. Reprinted with permission 
from Massachusetts Medical Society
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were lower than the starting dose, whereas 55 patients 
received higher doses (15, 20, or 25 mg twice daily) [98]. 
Dose reduction should be considered when a patient has a 
hemoglobin value in the range of 100 to <120 g/L and a 
platelet count of 75 to <100 × 109/L. Dose reductions and 
interruptions are recommended if hemoglobin is >100 and 
>80 g/L, respectively, or platelet count is <75 × 109 and 
<50 × 109/L, respectively (for additional detail, see full 
prescribing information [20]).
General safety considerations
Based on the pharmacokinetic profile of ruxolitinib, it 
is recommended that for concurrent administration with 
strong CYP3A4 inhibitors, the starting dose of ruxolitinib 
be reduced (Table 3) [20]. Patients already on a stable dose 
of ruxolitinib should also have their dose reduced if they 
begin taking a strong CYP3A4 inhibitor. Strong CYP3A4 
inhibitors include but are not limited to boceprevir, 
clarithromycin, conivaptan, indinavir, itraconazole, keto-
conazole, lopinavir, mibefradil, nefazodone, nelfinavir, 
posaconazole, ritonavir, saquinavir, telaprevir, telithro-
mycin, and voriconazole. Because fluconazole is both a 
CYP3A4 and CYP2C9 inhibitor, it should not be taken at 
doses greater than 200 mg daily concomitantly with rux-
olitinib. Furthermore, ingestion of grapefruit or grapefruit 
juice should be avoided in patients receiving ruxolitinib. 
Apart from grapefruit, ruxolitinib can be taken with or 
without food, as administration with food including high-
fat, high-calorie meals versus administration without food 
met the bioequivalence criteria for bioavailability [20].
Renal and hepatic impairment
Patients with renal or hepatic impairment exhibit altered 
pharmacokinetic properties of ruxolitinib and/or its metab-
olites [100]. Renal impairment had no effect on ruxolitinib 
pharmacokinetics but increased the exposure of ruxolitinib 
metabolites, with the greatest effect seen in patients with 
end-stage renal disease. Because these changes were asso-
ciated with increased pharmacodynamic activity (inhibi-
tion of STAT3 phosphorylation) [100], dose reductions 
are recommended for patients with moderate or severe 
renal disease. Ruxolitinib is not recommended for patients 
with end-stage renal disease, unless they are on dialysis 
(Table 5) [20]. Hepatic impairment did not affect maximal 
Table 4  Hematologic adverse eventsa from start of study drug to 
week 32 of the RESPONSE trial, regardless of relation to study drug 
[98]
a New or worsening hematologic events based on laboratory values
Percent of patients  
with any grade event  






Anemia 43.6 (0.9/0.9) 30.6 (0/0)
Thrombocytopenia 24.5 (4.5/0.9) 18.9 (2.7/0.9)
Lymphopenia 43.6 (15.5/0.9) 50.5 (16.2/1.8)
Leukopenia 9.1 (0.9/0) 12.6 (1.8/0)
Neutropenia 1.8 (0/0.9) 8.1 (0.9/0)
Table 5  Dosing of ruxolitinib 
in patients with renal or hepatic 
impairment [20]
CrCl creatinine clearance, MF myelofibrosis, PV polycythemia vera
Population Platelet count Ruxolitinib starting dose
Renal impairment
 MF: moderate (CrCl 30–59 mL/min) or 
severe (CrCl 15–29 mL/min) impairment
>150 × 109/L No dose modification
100 × 109 to 150 × 109/L 10 mg twice daily
50 × 109 to <100 × 109/L 5 mg daily
<50 × 109/L Not recommended
 PV: moderate or severe impairment Any 5 mg twice daily
 MF or PV: end-stage renal disease 
(CrCl < 15 mL/min) on dialysis
>200 × 109/L 20 mg once after dialysis session
100 × 109 to 200 × 109/L 15 mg once after dialysis session
 MF or PV: end-stage renal disease 
(CrCl < 15 mL/min) not requiring 
dialysis
Any Not recommended
Hepatic impairment (mild to severe)
 MF >150 × 109/L No dose modification
100 × 109 to 150 × 109/L 10 mg twice daily
50 × 109 to <100 × 109/L 5 mg daily
<50 × 109/L Not recommended
 PV Any 5 mg twice daily
1136 Cancer Chemother Pharmacol (2016) 77:1125–1142
1 3
serum concentration but increased exposure (by a factor 
of approximately 1.5–2) and decreased clearance, with no 
obvious quantitative relationship to the severity of impair-
ment [100]. Accordingly, lower starting doses are recom-
mended for all patients with MF or PV who have mild to 
severe hepatic impairment (Table 5) [20].
Risk of infection
In vitro and ex vivo evidence of inhibition of dendritic cell 
function and downregulation of T regulatory cells with 
ruxolitinib [101–103] suggests that ruxolitinib may have 
immunosuppressive activity. However, ruxolitinib does 
not appear to inhibit the formation of T cells, as evidenced 
by the successful immune reconstitution experienced by 
patients who received ruxolitinib and stem cell transplan-
tation [104]. Nonetheless, isolated cases of serious infec-
tions have been noted in patients with MF who were treated 
with ruxolitinib in clinical practice, including progressive 
multifocal leukoencephalopathy [105], increase in hepa-
titis B viral titers [106], reactivation of herpes simplex 
virus [107], and disseminated tuberculosis [108]. Further-
more, herpes zoster and urinary tract infections occurred in 
patients treated with ruxolitinib in phase 3 trials in MF and 
PV [20]. Because of the potential for bacterial, fungal, or 
viral infections to occur or be reactivated in patients receiv-
ing ruxolitinib, special care should be taken when treat-
ing patients with MF who have an already compromised 
immune system due to other underlying medical problems 
or comorbidities, or those who have a history of atypical 
infections. Patients should be observed for signs of infec-
tion so that proper treatment can begin promptly, and rux-
olitinib should not be started until serious infections have 
resolved. Patients at risk of tuberculosis (i.e., patients who 
have a history of tuberculosis, have lived in or traveled to 
countries with a high prevalence of tuberculosis, or have 
had close contact with a person with active tuberculosis) 
should be tested for latent infection prior to starting rux-
olitinib. Those who test positive should consult with their 
physician regarding the use of ruxolitinib based on their 
overall benefit-risk ratio [20].
Cardiac safety
The effect of single-dose ruxolitinib (25 and 200 mg) on 
the QTc interval was evaluated in a randomized, placebo- 
and active-controlled (moxifloxacin 400 mg) four-period 
crossover thorough QT study in 47 healthy human par-
ticipants [109]. In this study, which had a demonstrated 
ability to detect small effects, the upper bound of the one-
sided 95 % CI for the largest placebo-adjusted, baseline-
corrected QTc (Fridericia correction method) was <10 ms, 
which is below the level of regulatory concern. The dose of 
200 mg is adequate to represent the high-exposure clinical 
scenario [20].
Future directions
Although ruxolitinib has proven to provide unprecedented 
clinical benefits for patients with MF in terms of spleen 
size reduction, symptom alleviation, and improvements 
in measures of quality of life, it has also become clear 
in recent years that single target-directed therapies are 
unlikely to provide high levels of responses against the 
underlying clonal neoplasm in a majority of patients with 
advanced disease. Despite the fact that ruxolitinib targets 
the most critical pathway driving neoplastic proliferation in 
MPNs (i.e., the JAK2-STAT pathway), its capacity to elicit 
significant molecular responses (i.e., allele burden reduc-
tions) and/or bone marrow morphologic responses such as 
reversal of fibrosis in MF appears to be limited to a minor-
ity of patients and are generally only achieved with sus-
tained long-term therapy [77, 78]. It has been hypothesized 
that inflammation-imprinting of the bone marrow stroma 
in PMF by mutant clonal hematopoietic cells eventually 
results in changes in the stroma that protect the mutant 
clones against JAK2 inhibitor therapy [110]. This may 
explain, at least in part, why ruxolitinib is highly effec-
tive in providing rapid relief from MF-related symptoms, 
which to a large extent are attributed to excess inflamma-
tory cytokine expression, without having a major effect on 
clonal proliferation in patients with advanced MF [21, 61]. 
Similarly, the survival benefit observed with ruxolitinib in 
these patients is likely the result of effective disruption of 
the vicious cycle of self-sustaining inflammation and the 
consequent improvement of overall clinical status rather 
than of the moderate effects on myeloproliferation. Further 
improvement of survival in patients with MF may come 
from combination therapies of ruxolitinib with agents that 
target complementary pathogenic pathways, inhibit aber-
rant epigenetic modification (e.g., histone deacetylation), 
and help to reverse fibrosis in the bone marrow; these novel 
therapeutic approaches are currently being evaluated in 
numerous early-phase clinical trials [111].
Conclusions
Results of phase III clinical trials have demonstrated that 
the JAK1 and JAK2 inhibitor ruxolitinib provides signifi-
cant clinical benefits for patients with advanced MF and 
patients with PV who have had inadequate response to or 
are intolerant of hydroxyurea, including but not limited 
to reduction of splenomegaly and symptom burden in MF 
and PV and hematocrit control in PV. These findings are 
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consistent with the critical involvement of dysregulated 
JAK–STAT in the pathobiology of both diseases, irrespec-
tive of the type of pathogenic mutations. Although rux-
olitinib is not curative, current evidence suggests that it 
improves overall QoL, has prolonged survival in controlled 
clinical trials of patients with MF, and in some cases may 
lead to complete resolution of bone marrow fibrosis. Rux-
olitinib is generally well tolerated but its myelosuppres-
sive activity may lead to de novo or worsening cytope-
nias, particularly in patients with advanced MF, who often 
have disease-related anemia and/or low platelet counts. 
Careful monitoring of complete blood counts and prompt 
dose adjustments, particularly during the first 3 months of 
therapy, are essential tools of patient management to avoid 
dose-dependent cytopenias and ensure sustained, uninter-
rupted therapy, which in turn is required to maintain treat-
ment responses.
In summary, ruxolitinib is appropriate for the treatment 
of splenomegaly and MF-related symptoms in patients with 
intermediate- or high-risk MF who have a platelet count of 
≥50 × 109/L and do not qualify or opt for allogeneic hema-
tologic stem cell transplantation. Ruxolitinib-mediated reduc-
tions in spleen size and symptom burden, and even improve-
ment of survival appear not to be dependent on the patient’s 
mutation profile [75]. However, the ultimate treatment deci-
sion should be based for each patient on the totality of patient- 
and disease-specific criteria, including age, performance-sta-
tus, risk category, mutation profile, degree of symptoms and 
splenomegaly, and presence of disease-related cytopenias. In 
PV, ruxolitinib should be considered as a treatment option for 
patients with uncontrolled hematocrit who are refractory to 
or do not tolerate hydroxyurea, particularly if the patient also 
has splenomegaly and/or PV-related symptoms.
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